Российское диализное общество

Просмотр статьи

<< Вернуться к списку статей журнала

Том 10 №3,4 2008 год - Нефрология и диализ

Уремический синдром и уремические токсины (Обзор литературы)


Ермоленко В.М. Михайлова Н.А. Батэрдэнэ С.

Аннотация: Термин уремия, предложенный в 1840 г. P. Piorry и D. L’Heritier [121], произошел в результате слияния двух древнегреческих слов ouron (моча) и haima (кровь) и буквально означает “моча в крови”. Каким образом кровь становится похожей на мочу и последствия этой трансформации стали предметом изучения на протяжении нескольких веков.

Весь текст



Ключевые слова: уремический синдром, уремические токсины, гуанидины, диметиларгинины, средние молекулы

Список литературы:
  1. Яновский М.В. Об аналогии между некоторыми формами уремии и хроническими отравлениями вообще. Еженед. клин. газета 1886; 24.
  2. Abel M., Rithaler U., Zhang Y. et al. Expression of receptors for advanced glycosylated end-products in renal disease. NDT 1995; 10: 1662-1667.
  3. Addison T. On the disorders of the brain connected with diseased kidneys. Guy’s Hosp Rep 1839; 4: 1-9.
  4. Almdal T., Egfjord M., Hansen B., Vilstrup H. Increased hepatic capacity of urea synthesis in acute and chronic uraemia in rats. Clin Nutr 1991; 10: 206-212.
  5. Altmann P., Sawyer N., Cunningham J., Marsh F. Pterin metabolism in hemodialysis patients. Pteridines 1989; 1: 111-117.
  6. Amann K., Wiest G., Mall G. et al. A role of parathyroid hormone for the activation of cardic fibroblasts in uremia. J Am Soc Nephrol 1994; 4: 1814-1819.
  7. Anderson I., Mullen W., Meeker J. et al. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of literature. Ann intern Med 1996; 124: 726-734.
  8. Anderstam B., Katzarski K., Bergström J. Serum levels of N-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 1997; 8: 1437-1442.
  9. Asaba H., Bergström J., Fürst P. et al. The effect of renal transplantation on middle molecules in plasma and urine. Clin Nephrol 1977; 8: 329-334.
  10. Asaba H., Alvestrand A., Bergström J. et al. Uremic middle molecules in non-dialyzed azotemic patients: relation to symptom and clinical biochemistries. Clin Nephrol 1982; 17: 90-95.
  11. Asaba H. Accumulation and excretion of middle molecules. Clin Nephrol 1983; 19: 116-123.
  12. Asaba H., Alvestrand A., Fürst P. et al. Clinical implications of uremic middle molecules in regular hemodialysis patients. Clin Nephrol 1983; 19: 179-187.
  13. Baba S., Watanabe Y. Fecal methylamine and dimethylamin in chronic renal failure. Analyt Biochem 1988; 175: 252-257.
  14. Babb A., Popovich R., Christopher T. et al. The genesis of the square-metre-hour hypotesis. Trans Am Soc Artif Int Organs 1971; 17: 81-91.
  15. Babb A., Farrell P., Uvelli D. et al. Hemodialyser evaluation by examination of solute molecular spectra. Trans Am Soc Artif Int Organs 1972; 18: 98-105.
  16. Bachrach U., Wand Y., Tabib A. Polyamines: new cues in cell signal transduction. News Physiol Sci 2001; 16: 106-109.
  17. Baker H., Frank J., Bacchi C. et al. Biopterin content of human and rat fluids and tissues determined protozoologically. Am J Clin Nutr 1974; 27: 1247-1253.
  18. Bammens B., Evenepoel P., Verbeke K. et al. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relative with uremic symptoms. Kidney int 2003; 64: 2238-2243.
  19. Bammens B., Evenepoel P., Keuleers H. et al. Free serum concentration of the protein-bound retention solute p-cresol predicts mortality in hemodialysis patients. Kidney int 2006; 69: 1081-1087.
  20. Baylis C., Mitruka B., Deng A. Chronic blockade of nitric oxide synthesis in the rat produced systemic hypertension and glomerular damage. J Clin Investig 1992; 90: 278-281.
  21. Bergström J., Fürst P., Zimmerman L. Uremic middle molecules exist and are biologically active. Clin Nephrol 1979; 11: 229-238.
  22. Bergström J. Uremia is an intoxication. Kidney int 1985; 28; Suppl 17: S2-S4.
  23. Bode-Böger S., Boger R., Kienke S. et al. Elevated L-arginine dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219: 598-603.
  24. Bode-Böger S., Scalera F., Kielstein J. et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent coronary artery disease. J Am Soc Nephrol 2006, 17: 1128-1134.
  25. Boerhaave H. In: Van Swieten G. Commentaria in Hermanii Boerhaave aphorismos. Paris: 1773; 4; 1229: 168.
  26. Bostom A., Shemin D., Lapane K. et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114: 93-103.
  27. Boushey C., Beresford S., Omenn G., Motulsky A. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-1057.
  28. Brune B., Hartzell P., Nicotera P., Orrenius S. Spermine prevents endonuclease activation and apoptosis in thymocytes. Exp Cell Res 1991; 195: 323-329.
  29. Bucala R., Tracey K., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Investig 1991; 87: 432-438.
  30. Cameron J. Towards the millennium: the history of renal anemia and the rational use of epoietin. NDT 1999; 44 (Suppl 2): 10-21.
  31. Chapman G., Ward R., Farrell P. Separation and quantification of the “middle molecules” in uremia. Kidney int 1980; 17: 82-88.
  32. Christenson R. On granular degeneration of the kidney and their connection with albuminuria etc. Ed. Adamand Black, Edinburgh: 1839.
  33. Clarke R., Robinson K., Naughten E. et al. Hyperhomocysteinemia an independent risk factors for vascular disease. N Engl J Med 1991; 324: 1149-1155.
  34. Cohen B. Guanidinosuccinic acid in uremia. Arch intern Med 1970; 126: 846-850.
  35. Cohen G., Glorieux G., Thornalley P. et al. Review on uraemic toxins III. Recommendation for handling uraemic retention solutes in vitro-towards a standardized approach for research on uraemia. NDT 2007; 22: 3381-3390.
  36. Cooke J. Asymmetric dimethylarginine: the uber marker? Circulation, 2004; 109: 1813-1818.
  37. Curtis H., Mettler M., Ettlinger L. Study of intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr 1976; 126: 569-580.
  38. De Smet R., David F., Sandra P. et al. A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 1998; 278: 1-21.
  39. De Smet R., Kaer J. van., Vlem B. van et al. Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chemistry 2003; 49: 470-478.
  40. Deguchi T., Ohtsuki S., Otagiri M. et al. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney int 2002; 61: 1760-1768.
  41. Descombes E., Perriard F., Fellay G. Diffusion kinetics of urea, creatinine and uric acid in blood during hemodialysis: clinical implications. Clin Nephrol 1993; 40: 286-295.
  42. D’Hooge R., Rei Y., Marescan B., De Deyn P. Convulsive action and toxicity of uremic guanidine compounds: behavioral assessment and relation to brain concentration in adult mice. J Neurol Sci 1992; 112: 96-105.
  43. Don L., Bertrand E., Cereni C. et al. The uremic solutes p-cresol and indoxyl inhibit endothelial proliferation and wound repair. Kidney int 2004; 65: 442-451.
  44. Eknoyan G., Beck G., Chenng A. et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. New Engl J Med 2002; 347: 2010-2019.
  45. Elliott A., Elliott J. Voltage-dependent inhibition of RCK1 K+ channels by phenol, p-cresol and benzyl alcohol. Mol Pharmacol 1997; 51: 475-483.
  46. Eloot S., Torremans A., De Smet R. et al. Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the compounds. Kidney int 2005; 67: 1566-1575.
  47. Enomoto A., Takeda M., Tojo A. et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 2002; 13: 1711-1720.
  48. Evenepoel P., Claus D., Geypens B. et al. Evidence for impaired assimilation and increased colonic fermentation of protein related to gastric acid suppression therapy. Aliment Pharmacol Ther 1998; 12: 1011-1019.
  49. Fagner P., Man N., Cueille G. et al. Improved separation and quantification of the “middle molecules” G4-2 in uremia. Clin Chem 1983; 29: 703-707.
  50. Fourcroy A., Vanquelin N. Premoire pour service a’ l’histoire naturelle, chemique et medicale de l’urine humanie contenant quelques traits nouveaux sur son analyse et son alterations spontanee. Ann Chemie 1779; 31: 48-71.
  51. Fourcroy A., Vanquelin N. Nouvelles experiences sur l’uree. Ann Mus Histoire Naturelle 1808; 11: 226.
  52. Frerichs T. Die Brightsche Nierenkrankheit und deren Behandlung. Vieweg and Sohn, Braunschweig, 1851.
  53. Geypens B., Clans D., Evenepoel P. et al. Influence of dietary protein supplementations on the formation of bacterial metabolites in the colon. Gut 1977; 41: 70-76.
  54. Giovannetti S., Biagini M., Balestri P. Uremia-like syndrome in dogs chronically intoxicated with methylguanidine and creatinine. Clin Sci 1969; 36: 445-452.
  55. Giovanetti S., Balestri P., Barsotti G. Methylguanidine in uremia. Arch intern Med 1973; 131: 709-713.
  56. Glorieux G., Dhondt A., Jacobs P. et al. In vitro study of the potential role of guanidines in leucocyte function related atherogenesis and infection. Kidney int 2004; 65: 2184-2192.
  57. Goonasekera C., Rees D., Woolard P. et al. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997; 15: 901-909.
  58. Gradman A., Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis 2006; 48: 326-341.
  59. Haag-Weber M., Mai B., Hörl W. Isolation of granulocyte inhibitory protein from uremic patients with homology of b2-microglobulin. NDT 1994; 9: 382-388.
  60. Haalas J., Gajiwala K., Maffei M. et al. Weight-reduction effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543-546.
  61. Haase M., Bellomo R., Baldwin L. et al. b2-microglobulin removal and plasma albumin levels with high cut-off hemodialysis. IJAO 2007; 30: 385-392.
  62. Harpel P., Zhang X., Borth W. Homocysteine and hemostasis: pathogenetic mechanisms predisposing to thrombosis. J Nutr 1996; 126: 1285S-1289S.
  63. Heimbeіrger O., Lönnqvist F., Danielsson A. et al. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 1997; 8: 1423-1430.
  64. Hida M., Aiba Y., Samamura S. et al. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the foods after oral administration of Lebenin, a lactic acid bacteria preparation in uremic patients undergoing hemodialysis. Nephron 1996; 74: 349-355.
  65. Hohenegger M., Vermes M., Esposito R., Giordano C. Effect of some uremic toxins on oxygen consumption of rats in vivo and in vitro. Nephron 1988; 48: 154-158.
  66. Hörl W, Haag-Weber M., Georgopoulos A., Block L. Physiochemical characterization of polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci USA 1990; 87: 6353-6357.
  67. Horowitz H. Uremic toxins and platelet function. Arch intern Med 1970; 7, 823.
  68. Ihle B., Cox R., Dunn S., Simenhoff M. Determination of body burden of uremic toxins. Clin Nephrol 1984; 22: 82-89.
  69. Imani F., Horii Y., Suthanthiran M. et al. Advanced glycosylation end-product specific receptor on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J exp Med 1993; 178: 2165-2172.
  70. Jankowski J., Giet M., Jankowski V. et al. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Investig 2003; 112: 256-254.
  71. Johansen K., Mulligan K., Tai V., Shambelan M. Leptin body composition and induces of malnutrition in dialysis patients. J Am Soc Nephrol 1997; 8: 195A.
  72. Johnes R., Moscicki J., Difazio C. Nitric oxide synthase inhibitor dose-dependently and reversibly reduces the threshold for halothane anesthesia: a role for nitric oxide in mediating consciousness. Anesthesiology 1992; 77: 779-784.
  73. Johnson W., Hagge W., Wagoner R. et al. Effects of urea loading in patients with far-advanced renal failure. Mayo Clin Proc 1972; 47: 21-29.
  74. Kabanda A., Jadonl M., Pochet J. et al. Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. Kidney int 1994; 45: 1689-1696.
  75. Kaneda Y., Suga A. Usefulness of serum neopterin in renal transplantation considering the neopterin/creatinine ratio. Nephron 1988; 49: 259-260.
  76. Keweloh H., Diefenbach R., Rehm H. Increase of phenol tolerance of Escherichia coli by alteration of the fatty acid composition of the membrane lipid. Arch Microbiol 1991; 157: 49-53.
  77. Kielstein J., Böger R., Bode-Böger S. et al. Low dialysance of asymmetric dimethylarginine (ADMA)-in vivo and in vitro evidence of significant protein binding. Clin Nephrol 2004; 62: 295-300.
  78. Kielstein J., Impraim B., Simmel S. et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginin in humans. Circulation 2004; 109: 172-177.
  79. Kielstein J., Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and uremic toxin coming of age? Am J Kidney Dis 2005; 46: 186-202.
  80. Kielstein J., Donnerstag F., Gasper S. et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006; 37: 2024-2029.
  81. Kishore B. Some observations on the in vivo and in vitro effects of guanidinosuccinic acid on the nervous system of laboratory animals. Acta Med Bio 1983; 31: 79-85.
  82. Kopple J., Gordon S., Wang M., Swendseid M. Fact nnvbvvnvnvnnnnnnnnnnnnnnnnnnnnnnnnnnnbors affecting serum and urinary guanidinosucicinic acid level in normal and uremic subjects. J Lab Clin Med 1977; 90: 303-311.
  83. Kusher D., Beckman B., Nguyen L. et al. Polyamines in the anemia of end-stage renal disease. Kidney int 1991; 39: 725-732.
  84. Lamb E., Cattell W., Dawney A. In vitro formation of advanced glycation products in peritoneal dialysis fluid. Kidney int 1995; 47: 1768-1774.
  85. Lascelles P., Taylor W. The effect upon tissue respiration in vitro metabolites which accumulate in uremic coma. Clin Sci 1966; 31: 403-413.
  86. Leeming R., Blair J., Melikian V., O´Gorman D. Biopterin derivatives in human body fluids and tissues. J Clin Pathol 1976; 29: 444-451.
  87. Leuwenhoek A. van, Observations D. Anthonii Leuwenhoek de natis e semine genitali animalcules. Phil Trans 1678; 12: 1040-1043.
  88. Liew F., Millott S., Parkinson C. et al. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 1990; 144: 4794-4797.
  89. Lim J., Gasson C., Kaji D. Urea inhibits NaK2Cl cotransport in human erythrocytes. J Clin Invest 1995; 96: 2126-2132.
  90. Loor H. de., Bammens B., Evenepoel P. et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic serum and normal serum. Clin Chem 2005; 51: 1535-1538.
  91. MacAllister R., Whitley G., Vallance P. Effects of guanidine and uremic compounds on nitric oxide pathways. Kidney int 1994; 45: 737-742.
  92. MacAllister R., Rambausek M., Vallance P. et al. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. NDT 1997; 11: 2449-2452.
  93. Mani N. La deconverte de l’uremie experimentale par Jean-Lous Prevost et Jean Batiste Dumas. Geneve: Med Hyg 1821; 1963, 21: 408-409.
  94. Martinez A., Recht N., Hostetter T., Meyer T. Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16: 3430-3436.
  95. Massry S., Smogorzewski M. Mechanisms through which parathyroid hormone mediated its deleterious effects on organ function in uremia. Semin Nephrol 1994; 14: 219-231.
  96. Massry S., Smogorzewski M. Parathyroid hormone, chronic renal failure and the liver. Kidney int 1997; 52; Suppl. 62: S5-S7.
  97. Matsuoka H., Itoh S., Kimoto M. et al. Asimmetrical dimethylarginine, an endogenous nitric oxide inhibitor, in experimental hypertension. Hypertension 1997; 29: 242-247.
  98. Maxfield F., Willingham M., Davies P., Pastan I. Amines inhibit the clustering of a2-macroglobulin and EGF on the fibroblast cell surface. Nature 1979; 277: 661.
  99. Meinnitzer A., Seelhorst U., Wellnitz B. et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem 2007; 53: 273-283.
  100. Menyhart J., Grof J. Many hitherto unknown peptides are principal constituents of “uremic” middle molecules. Clin Chem 1981; 27: 1712-1716.
  101. Miyata T., Inagi R., Iida Y. et al. Involvement of b2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Investig 1994; 93: 521-528.
  102. Miyata T., Ueda T., Shinzato T. et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implication in the pathophysiology of pentasidine. J Am Soc Nephrol 1996; 7: 1198-1206.
  103. Miyazaki H., Matsuoka H., Cooke J. et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-1146.
  104. Monti J., Brunet P., Berland Y. et al. Opposite effects of urea on hemoglobin-oxygen affinity in anemia in chronic renal failure. Kidney int 1995; 48: 827-831.
  105. Morrisey J., Klahr S. Enalapril decreases nuclear factor kB activation in the kidney with urethral obstruction. Kidney int 1997; 52: 926-933.
  106. Motojima M., Nishuima F., Ikoma M. et al. Role for “uremic toxin” in progressive loss of intact nephrons in chronic renal failure. Kidney int 1991; 40: 461-469.
  107. Motojima M., Hosokawa A., Yamato H. et al. Uraemic toxins induced proximal tubular injury via organic anion transporter 1-mediated uptake. Br J Pharmacol 2002; 135: 555-563.
  108. Motojima M., Hosokawa A., Yamato H. et al. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kB and free radical in proximal tubular cells. Kidney int 2003; 63: 1671-1680.
  109. Nitta T., Igarashi K., Yamashita A. et al. Involvement of polyamines in B cell receptor-mediated apoptosis: spermine function as negative modulators. Exp Cell Res 2001; 265: 174-183.
  110. Niwa T., Miyazaki T., Hashimoto N. et al. Suppressed serum and urine levels of indoxil sulfate by oral sorbent in experimental uremic rats. Am J Nephrol 1992; 12: 201-206.
  111. Niwa T., Miyazaki T., Tsukushi S. et al. Accumulation of indoxil-beta-D-glucuronide in uremic serum: supression of its production by oral sorbent and efficient removal by hemodialysis. Nephron 1996; 74: 72-78.
  112. Niwa T., Nomura T., Sugiyama S. et al. The protein metabolism hypothesis a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney int 1997; 52: Suppl. 62: S23-S28.
  113. Oda T., Yung Y., Kim H. et al. PAI-1 deficiency attenuates the fibrigenic response to uretral obstruction. Kidney int 2001; 60: 587-596.
  114. Owen W., Lew N., Liu Y. et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329: 1001-1006.
  115. Panichi V., Mantuano E., Paoletti S. et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol 2008; 21: 38-44.
  116. Papanastasion P., Grass L., Rodela H. et al. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney int 1994; 46: 216-222.
  117. Patel S., Koenig R., Hsu C. Effect of Schiff base formation on the function of the calcitriol receptor. Kidney int 1996; 50: 1539-1545.
  118. Pelleymounter M., Cullen M., Baker M. et al. Effects of the obese gene produce on body weight regulation in ob/ob mice. Science 1995; 269: 540-543.
  119. Peri A., Cordella-Mielle E., Mielle E., Mukherjee A. Tissue specific expression of gene coding for human Clara cell 10-kD protein, a phospholipase A2-inhibitor protein. J Clin Investig 1993; 92: 2099-2109.
  120. Perry T., Young V., Kish S. et al. Neurochemical abnormalities in brains of renal failure patients treated by repeated hemodialysis. J Neurochem 1985; 45: 1043-1048.
  121. Piorry P., L’Heritier D. Traite des Alterations du Sang. Bailliere. Paris: 1840.
  122. Piorry P. Traite de Medicine pratique. Paris: 1847; III, Chapter XII: 4430-4440.
  123. Prevoust J., Dumas J. Examin du sang et de son action dans les divers phenomenes de la vie. Ann. Chimie Physique. Paris: 1823; 23: 90-104.
  124. Rao D., Shih M., Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993; 328: 171-175.
  125. Ravani P., Tripepi G., Malberti F. et al. Asymmetric dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competive risk modeling approach. J Am Soc Nephrol 2005; 16: 2254-2256.
  126. Rayer P. Traite des maladies des reins et les alterations de l’urine. Paris 1839-1841. Three volumes and atlas.
  127. Rees D., Palmer R., Moncada S. Role of endothelium derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 3375-3378.
  128. Rerolle J., Hertig A., Nguen G. et al. Plasminogen activator inhibitor type 1 is a potential target in renal fibrosis. Kidney int 2000; 58: 1841-1850.
  129. Roberts W. Practical treatise on renal and urinary diseases. London: 1865.
  130. Robinson K., Gupta A., Dennis V. et al. Hyperhomocysteinemia confers an independent risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 2743-2748.
  131. Rock D., MacDonald R. Spermine and related polyamines produce a voltage-dependent reduction of N-methyl-d-aspartate receptor single-channel conductance. Mol Pharmacol 1992; 42: 157-164.
  132. Rottenbourg J. Residual renal function and recovery of renal function in patients treated by CAPD. Kidney int 1993; 43 (Suppl. 40): S106-S110.
  133. Rutkowski B., Slominska E., Szolkewicz M. et al. N-methyl-2-pyridon-5-carboxamide: a novel uremic toxin? Kidney int 2003; 84: S19-S21.
  134. Rutkowski B. Are so-called uremic toxins always toxic? J Renal Nutrition 2008; 18: 7-11.
  135. Sanaka T., Sugino N., Teraoka S, Ota K. Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis 1988; 12: 97-103.
  136. Schabel R., Blankenberg S., lubos E. et al. Asymmetric dimethylarginine and risk cardiovascular events and death in patients with coronary artery disease: results from AtheroGene Study. Circ Res 2005; 97: e53-e59.
  137. Schepers E., Meert N., Glorieux G. et al. P-cresylsulfate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. NDT 2007; 22: 592-596.
  138. Schottin E. Beiträge zur Charakteristik der Urämie. Arch Physiol Heilk 1853; 12: 170-192.
  139. Schultre F., Lenzen H., Hanefeld C. et al. Asymmetric dimethylarginine is an independent risk factor for coronary artery heart disease: results from the multicentre Coronary Artery Risk Determination investigating the influence of ADMA Concentration (CARDIAC) Study. Am Heart J 2006; 152: 493-498.
  140. Segalas d’Etchepare, Vanquelin N. Sur de nouvelles experiences relatives aux proprietes medicamentences de l’uree. J Physiol 1821-1822; 2: 254.
  141. Sharma K., Considine R., Michael B. et al. Plasma leptin is partly cleared by the kidney and its elevated in hemodialysis patients. Kidney int 1997; S1: 1980-1985.
  142. Simenhoff M. Metabolism and toxicity of aliphatic amines. Kidney int 1975; 7: Suppl. 314.
  143. Simenhoff M., Burke J., Saukkonen J. et al. Biochemical profile of uremic breath. N Engl J Med 1977; 297: 132-135.
  144. Simenhoff M., Saukkonen J., Burke J. et al. Importance of aliphatic amines in uremia. Kidney int 1978; 13: S16-S19.
  145. Slavin R., Fitch C. Inhibition of lymphocyte transformation by guanidinosuccinic acid, a surplus metabolite in uremia. Experimentia 1971; 27: 1340-1345.
  146. Slominska E., Kowalik K., Smolenski R. et al. Accumulation of poly (ADP-ribose) polymerase inhibition in children with chronic renal failure. Pediatr Nephrol 2006; 21: 800-806.
  147. Smogorzewski M, Massry S. Uremic cardiomyopathy: role of parathyroid hormone. Kidney int 1997; 52; Suppl. 62: S12-S14.
  148. Sorrentino R., Pinto A. Effect of methylguanidine on rat blood pressure: role of endothelial nitric oxide synthase. Br J Pharmacol 1995; 115: 510-514.
  149. Spoto B., Pariongo R., Pariongo G. et al. The enzymatic machinery for ADMA synthesis and degradation is fully expressed in human adipocytes. J Nephrology 2007; 20: 554-559.
  150. Stabellini G., Creati B., Di Primo R., Trubiani O. Intracellular distribution of polyamines in human lymphoblastoid cell line during phorbol-ester-induced differentiation. Biochem Mol Biol Int 1996; 39: 843-851.
  151. Stabellini G., Bosi G., Valeno V. et al. Relation between the osmolality trend and ornithyndecarboxylase activity in red blod cells of uremic patients during hemodialysis treatment. Biomed. Pharmacother 1998; 52: 166-168.
  152. Stabellini G., Locci P., Calivitti M. et al. Epithelial-mesenchymal interactions lung branching morphogenesis. Role polyamines and transforming growth factor B1. Eur J Histochem 2001; 45: 151-162.
  153. Stabellini G., Calastrini C., Scapoli L. et al. The effect of polyamines and dialysate fluid on extracellular matrix synthesis in VERO cell cultures. J Nephrol 2002; 15: 539-546.
  154. Stein I., Perez G., Johnson R., Cumming N. Serun levels and urinary excretion of methylguanidine in chronic renal failure. J Lab Clin Med 1971; 77: 1020-1021.
  155. Strauss H. Die chronische Nierenen-entzundingen. Berlin: 1902.
  156. Suliman M., Stenvinkel., Jogestrand T. et al. Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. Clin Nephrol 2006; 66: 418-425.
  157. Sullivan P., Murnaghan D., Callaghan N. et al. Cerebral transmitter precursors and metabolites in advanced renal disease. J Neurol Neurosurg Psych 1978; 41: 581-588.
  158. Szabo C., Southan G., Wood E. et al. Inhibition by spermine of the induction of the nitric oxide synthaze in J774,2 macrophages. Br J Pharmacol 1994; 112: 355-356.
  159. Tanaka A., Takahashi Y., Mizokuchi M. et al. Plasma, urinary and erythrocyte cоncentrations of guanidine compounds in patients with chronic renal failure. Renal Fail 1999; 21: 499-514.
  160. Thompson D., Perera K., Fisher R., Brendel K. Cresol isomers: comparison of toxic potency in rat liver slices. Toxicol Appl Pharmacol 194, 125: 51-58.
  161. Tiranathanagul K., Yossundharakul C., Techawathanawanna N. et al. Comparison of the middle-molecule clearance between convective control double high-flux hemodiafiltration and on-line hemodiafiltration. IJAO 2007; 30: 1090-1097.
  162. Tojo A., Welch W., Bremer V. et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney int 1997; 52: 1593-1601.
  163. Tsai C., Perrella M., Yoshizumi M. et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1992; 91: 10193-10197.
  164. Valkonen V., Paiva H., Salonen J. et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-2128.
  165. Vanholder R., Ringoir S. Adequacy of dialysis: a critical analysis. Kidney int 1992; 42: 540-558.
  166. Vanholder R., De Smet R., Lesaffer G. p-Cresol: a toxin revealing many neglected but relevant aspects of uremic toxicity. NDT 1999; 14: 2813-2815.
  167. Vanholder R., De Smet R., Glorieux G. et al. Review on uremic toxins: classification, concentration and interindividual variability. Kidney int 2003; 63: 1934-1943.
  168. Vanholder R., Meert N., Schepers E. et al. Review on uraemic solutes II-Variability in reported concentrations: causes and consequences. NDT 2007; 22: 3115-3121.
  169. Wardener de H. The Kidney. Churchill Levingstone, Edinburgh, 1973.
  170. Weisensee D., Lőw-Fridrich I., Riehle M. et al. In vitro approach to “uremic cardiomyopathy”. Nephron 1993; 65: 392-400.
  171. Weissinger E., Kaiser T., Meert N. et al. Proteomics: a novel tool to unravel the patho-physiology of uraemia. NDT 2004; 19: 3068-3077.
  172. Wengle B., Hellstrom K. Volatile phenols in serum of uraemic patients. Clin Sci 1972; 43: 493-498.
  173. White R., Barenfield D., Ram S., Work J. Peritoneal dialysis solutions reverse the hemodynamic effects of nitric oxide synthesis inhibitors. Kidney int 1995; 48: 1986-1993.
  174. Wills M. Uremic toxins and their effect on intermediary metabolism. Clin Chem 1985; 31: 5-13.
  175. Witko-Sarsat V., Friedlander M., Capeillere-Blandin C. et al. Advanced oxydatation protein products as a novel marker of oxidative stress in uremia. Kidney int 1996; 49: 1304-1313.
  176. Yano S., Yamaguchi T., Kanazawa I. et al. The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure. NDT 2007; 22: 3160-3165.
  177. Yokoyama M., Tabori C., Miller E., Hogberg M. The effects of antibiotics in the weanling pig diet on growth and the excretion of volatile phenolic and aromatic bacterial metabolites. Am J Clin Nutr 1982; 35: 1417-1424.
  178. Yokozawa T., Zun Li Mo., Oura H. Comparison of toxic effects of methylguanidin, guanidinosuccinic acid and creatinine in rats with adenin-induced chronic renal failure. Nephron 1989; 51: 388-392.
  179. Young G., Woodrow G., Kendall S. et al. Increased plasma leptin/fat ratio in patients with chronic renal failure: a cause of malnutrition? NDT 1997; 12: 2318-2323.
  180. Yu X., Li Y., Xiong Y. Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits. Life Sci 1994; 54: 753-758.
  181. Zoccali C., Bode-Beger S., Mallamaci F. et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117.
  182. Zoccali C., Benedetto F., Maas R. et al. Asymmetric dimethylarginine, C-reactive protein and carotid intima-media thikness in end-stage renal disease. J Am Soc Nephrol 2002; 13: 490-496.
  183. Zoccali C., Mallamaci F., Mass R. et al. Left ventricular hypertrophy, cardic remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney int 2002; 62: 339-345.
  184. Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and uremic toxin coming of age? Am J Kidney Dis 2005; 46, 186-202.

Другие статьи по теме


Навигация по статьям
Разделы журнала
Наиболее читаемые статьи
Журнал "Нефрология и диализ"